Bellerophon to Present Additional Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at American Thoracic Society 115th International Conference
Stock Information for Bellerophon Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.